

**Symmetry assisted tuning of bending and brittle multi-component forms
of probenecid**

Supporting Information

Probenecid	
IR, DSC, PXRD, face-indexing, attachment energies	S2
Probenecid : bipyridine co-crystal	
IR, DSC, PXRD, crystal data, face-indexing, attachment energies	S4
Probenecid : piperazine salt	
IR, DSC, PXRD, crystal data, face-indexing, attachment energies	S7
Probenecid : pyridine co-crystal	
IR, DSC, PXRD, crystal data, face-indexing, attachment energies	S10
Probenecid : acridine co-crystal	
IR, DSC, PXRD, crystal data, face-indexing, attachment energies	S13
Calculated and Reported pKa values for compounds 1–5	S16
References	S16




Figure 1. IR spectra for commercial probenecid.




Figure 2. DSC data for commercial probenecid, matching the literature.¹




Figure 3. PXRD data for probenecid: commercial (black) and theoretical (red).





Figure 4 Face-indexed photograph of probenecid.

Table 1 The attachment energies for probenecid.

Face	Slice Attachment.Energy, kcal mol ⁻¹
1 0 0	-21.27
0 1 0	-17.36
0 0 1	-7.04

**Figure 5.** IR spectra comparison for probenecid (blue), 4,4'-bipyridine (red) and the co-crystal (green).




Figure 6. DSC data for the probenecid : 4,4'-bipyridine co-crystal.




Figure 7. PXRD data for the probenecid : 4,4'-bipyridine co-crystal: experimental (black) and theoretical (red)

Crystallographic data for probenecid : bipyridine

$C_{36}H_{46}N_4O_8S_2$, $M= 726.89$, triclinic, $P-1$, $a=5.3240(11)$ Å, $b=7.8906(14)$ Å, $c=23.599(5)$ Å, $\alpha=85.158(9)^\circ$, $\beta=83.687(7)^\circ$, $\gamma=70.746(6)^\circ$, $V=929.0(3)$ Å 3 , $Z=2$, $D_c= 1.299$ g cm $^{-3}$, $F_{000}=386$, Mo K α radiation, $\lambda=0.7107$ Å, $T=300(2)$ K, $2\theta_{\text{max}}=26.4^\circ$, $\mu=0.199$ mm $^{-1}$, 10180 reflections collected, 3718 unique ($R_{\text{int}}=0.0388$), final $GooF=0.882$, $R_1=0.0591$, $wR_2=0.1795$, [2645 obs. Data: $I > 2\sigma(I)$]; $R_1=0.0864$, $wR_2=0.1556$, (all data).




Figure 8 Face-indexed photograph of probenecid : bipyridine.

Table 2 The attachment energies for probenecid : bipyridine.

Face	Slice Attachment.Energy, kcal mol $^{-1}$
1 0 0	-22.97
0 1 0	-15.22
0 0 1	-5.65




Figure 9. IR spectra comparison for probenecid (blue), piperazine (red) and salt (green).




Figure 10. DSC data for probenecid : piperazine salt.




Figure 11. PXRD data for probenecid: piperazine salt: experimental (black) and theoretical (red).

Crystallographic data for probenecid : piperazine

$C_{15}H_{24}N_2O_4S_1$, M=328.42, triclinic, $P-1$, $a=5.718(4)$ Å, $b=7.307(4)$ Å, $c=21.178(13)$ Å, $\alpha=92.355(17)$ °, $\beta=91.732(16)$ °, $\gamma=93.192(16)$ °, $V=882.3(9)$ Å 3 , $Z=2$, $D_c= 1.236$ g cm $^{-3}$, $F_{000}=352$, Mo K α radiation, $\lambda=0.7107$ Å, $T=300(2)$ K, $2\theta_{max}=26.61$ °, $\mu=0.201$ mm $^{-1}$, 8654 reflections collected, 3550 unique ($R_{int}=0.0627$), final $GooF=1.028$, $R_l=0.0708$, $wR_2= 0.2091$, [2108 obs. Data: $I > 2\sigma(I)$]; $R_l=0.1164$, $wR_2=0.1841$, (all data).




Figure 12 Face-indexed photograph of probenecid : piperazine.

Table 3 The attachment energies for probenecid : piperazine.

Face	Slice Attachment.Energy, kcal mol ⁻¹
1 0 0	-79.06
0 1 0	-71.75
0 0 1	-61.32




Figure 13. IR spectra comparison for probenecid (blue), pyridine (red) and co-crystal (green).




Figure 14. DSC data for probenecid : pyridine co-crystal.




Figure 15. PXRD data for probenecid : pyridine co-crystal: experimental (black) and theoretical (red).

Crystallographic data for probenecid : pyridine

$C_{18}H_{24}N_2O_4S_1$, $M=364.45$, monoclinic, $P2_1/c$, $a=7.4241(8)$ Å, $b=6.9988(8)$ Å, $c=37.621(4)$ Å, $\beta=94.210(4)$ °, $V=1949.5(4)$ Å 3 , $Z=4$, $D_c=1.242$ g cm $^{-3}$, $F_{000}=776$, Mo K α radiation, $\lambda=0.7107$ Å, $T=300(2)$ K, $2\theta_{max}=26.36$ °, $\mu=0.189$ mm $^{-1}$, 16381 reflections collected, 3897 unique ($R_{int}=0.0441$), final GooF=1.064, $R_1=0.0876$, $wR_2=0.2756$, [2773 obs. Data: $I > 2\sigma(I)$]; $R_1=0.1138$, $wR_2=0.2460$, (all data).




Figure 16 Face-indexed photograph of probenecid : pyridine.

Table 4 The attachment energies for probenecid : pyridine.

Face	Slice Attachment.Energy, kcal mol ⁻¹
0 0 2	-13.58
1 0 0	-18.73
1 0 -2	-23.62
0 1 -1	-18.42
1 0 2	-24.31
0 1 -2	-18.78
1 -1 0	-23.59
1 -1 -1	-26.06




Figure 17. IR spectra comparison for probenecid (blue), acridine (red) and co-crystal (green).




Figure 18. DSC data for probenecid : acridine co-crystal.




Figure 19. PXRD data for probenecid : acridine co-crystal: experimental (black) and theoretical (red)

Crystallographic data for probenecid : acridine

$C_{26}H_{28}N_2O_4S_1$, $M=464.56$, monoclinic, $P2_1/c$, $a=7.4752(7)$ Å, $b=31.526(3)$ Å, $c=10.6100(9)$ Å, $\beta=95.799(3)$ °, $V=2487.6(4)$ Å 3 , $Z=4$, $D_c = 1.240$ g cm $^{-3}$, $F_{000}=984$, Mo K α radiation, $\lambda=0.7107$ Å, $T=300(2)$ K, $2\theta_{max}=26.47$ °, $\mu=0.164$ mm $^{-1}$, 27198 reflections collected, 5107 unique ($R_{int}=0.0441$), final GooF=0.988, $R_1= 0.0419$, $wR_2= 0.988$, [3788 obs. Data: $I > 2\sigma(I)$]; $R_1= 0.0620$, $wR_2=0.1048$, (all data).




Figure 20 Face-indexed photograph of probenecid : acridine.

Table 5 The attachment energies for probenecid : acridine.

Face	Slice Attachment.Energy, kcal mol ⁻¹
0 2 0	-17.37
0 1 -1	-12.00
0 2 -1	-15.22
1 0 0	-12.32
1 -1 0	-14.90
1 -2 0	-19.88
1 -1 -1	-15.98




Figure 21 pKa values for probenecid and co-formers, calculated using MarvinSketch.²

Table 6 Reported and calculate pKa values for probenecid and co-formers.

Compound	pKa reported	pKa from MarvinSketch. ²
Probenecid	3.40 ³	3.53
Piperazine	9.73 ⁴	9.56
Bipyridine	4.82 ⁵	4.44
Acridine	5.62 ⁶	6.15
Pyridine	5.25 ⁷	5.12

References:

1. E. Nauha, and J. Bernstein, *J. Pharm. Sci.*, 2015, **104**, 2056-2061.
2. Marvin, 16.9.5.0, 2016, ChemAxon, <http://www.chemaxon.com>
3. Drug bank, <https://www.drugbank.ca/drugs/DB01032>
4. Drug bank, <https://www.drugbank.ca/drugs/DB00592>
5. C. Öğretir, İ. İ. Öztürk, and N. F. Tay, *ARKIVOC* 2009, xiv, 235– 254.
6. Y. Huh, J. -G. Lee, D. C. McPhail and K. Kim, *J. Solution Chem.*, 1993, **22**, 651-661.
7. I. -J. Chen and A. D. MacKerell Jr. *Theor. Chem. Acc.*, 2000, **103**, 483–494.